AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34510212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 35444972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on multivariate Cox regression model to predict cancer-specific survival (CSS) for 1-, 3-, and 5-years.
Number of subjects: 13105
Study 35444972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram validation methods including consistency index (C-index), calibration curve, and area under the Subject operating curve (AUC).
Number of subjects: 13105
Study 33675399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluoropyrimidine with and without Bevacizumab
Number of subjects: 550
Study 33675399 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 positive mCRC
Number of subjects: 550
Study 35357406 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturography-assisted vestibular retraining (12 twice-weekly sessions)
Number of subjects: 13
Study 34338481 — intervention group
Group type: EXPERIMENTAL
Intervention: Folitime® (225 IU/day for 5 days, followed by dose adaptation up to 450 IU/day)
Number of subjects: 93
Study 34338481 — intervention group
Group type: COMPARATOR
Intervention: Gonal-f® (225 IU/day for 5 days, followed by dose adaptation up to 450 IU/day)
Number of subjects: 93
Study 34338481 — intervention group
Group type: EXPERIMENTAL
Intervention: Folitime®
Number of subjects: 93
Study 34338481 — intervention group
Group type: COMPARATOR
Intervention: Gonal-f®
Number of subjects: 93
Study 34338481 — intervention group
Group type: EXPERIMENTAL
Intervention: Folitime® and Gonal-f®
Number of subjects: 93
Study 35623659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg administered intravenously on day 1 every 3 weeks and anlotinib 12 mg administered on days 1-14 in a 21-day cycle.
Number of subjects: 23
Study 35623659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus anlotinib
Number of subjects: 23
Study 33722102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise music (PreExM)
Number of subjects: 10
Study 33722102 — intervention group
Group type: COMPARATOR
Intervention: No music (NM)
Number of subjects: 10
Study 36068109 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi-Mcat vaccine
Number of subjects: 571
Study 36068109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 33592844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine enteric-coated tablets combined with Kangfuxin Liquid (KFX) enema
Number of subjects: 236
Study 33592844 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine enteric-coated tablets combined with placebo enema
Number of subjects: 236
Study 32404389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble Continuous Positive Airway Pressure (bCPAP)
Number of subjects: 54
Study 32404389 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen
Number of subjects: 54
Study 32404389 — intervention group
Group type: COMPARATOR
Intervention: Community perceptions of oxygen and bCPAP
Number of subjects: 54
Study 34922383 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.0 mg
Number of subjects: 0
Study 32252721 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness Beliefs about Cancer (ABC) measurement tool
Number of subjects: 1895
Study 35244227 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative inquiry into parents' experiences and preferences for ADHD treatment
Number of subjects: 23
Study 33029529 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on age, body mass index, FPG, and TC
Number of subjects: 1688
Study 33175128 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Number of subjects: 1260
Study 33175128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1260
Study 33356038 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered psychological support (FCPS)
Number of subjects: 84
Study 33356038 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 84
Study 35984870 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg of full spectrum extract of ashwagandha root per day for 30 days
Number of subjects: 60
Study 35984870 — intervention group
Group type: COMPARATOR
Intervention: Glycerol capsules (placebo)
Number of subjects: 60
Study 34196874 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat (5 mg) plus Exemestane (25 mg)
Number of subjects: 40
Study 34196874 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat (3, 5, or 7 mg/week)
Number of subjects: 40
Study 34196874 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat (5 mg)
Number of subjects: 40
Study 32985088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5, or 50 mg bid)
Number of subjects: 8256
Study 32985088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8256
Study 35113295 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Aware (intervention)
Number of subjects: 590
Study 33874756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 3358
Study 33874756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3358
Study 35081959 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 1304
Study 35081959 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Micronutrient Supplementation (MMNS)
Number of subjects: 1304
Study 35081959 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Micronutrient Supplementation (MMNS) and Physical Activity (PA)
Number of subjects: 1304
Study 35081959 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1304
Study 33979972 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax with low-dose cytarabine (LDAC)
Number of subjects: 15
Study 33979972 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low-dose cytarabine (LDAC)
Number of subjects: 15
Study 33957272 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat, Walk, Sleep (EWS)
Number of subjects: 188
Study 33957272 — intervention group
Group type: EXPERIMENTAL
Intervention: EWS + Medication Therapy Management (MTM)
Number of subjects: 188
Study 33957272 — intervention group
Group type: COMPARATOR
Intervention: Social Services (SS)
Number of subjects: 188
Study 32917440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG)
Number of subjects: 40
Study 32917440 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided palpation (LMGP)
Number of subjects: 40
Study 36479935 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐ACTION exercise intervention
Number of subjects: 1159
Study 33593072 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook recruitment strategy
Number of subjects: 348
Study 33593072 — intervention group
Group type: COMPARATOR
Intervention: Traditional recruitment campaign
Number of subjects: 348
Study 36339599 — intervention group
Group type: EXPERIMENTAL
Intervention: Juhongtanke oral solution (20 mL q8h for 5 days)
Number of subjects: 240
Study 36339599 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment alone (Control)
Number of subjects: 240
Study 33634939 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed digital artery island flap (RDAIF) with superficial vein anastomosis
Number of subjects: 92
Study 33634939 — intervention group
Group type: COMPARATOR
Intervention: Reversed digital artery island flap (RDAIF) without superficial vein anastomosis
Number of subjects: 92
Study 35710594 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for mild chronic hypertension in pregnancy
Number of subjects: 0
Study 35710594 — intervention group
Group type: EXPERIMENTAL
Intervention: Established antihypertensive therapy during pregnancy
Number of subjects: 0
Study 32957850 — intervention group
Group type: EXPERIMENTAL
Intervention: Alliance convergence in the patient-therapist working alliance
Number of subjects: 235
Study 32725873 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 134
Study 32725873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose NW Roselle
Number of subjects: 134
Study 32725873 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NW Roselle
Number of subjects: 134
Study 35099113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 15030
Study 35099113 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (as-needed) without antihypertensive medications
Number of subjects: 15030
Study 35099113 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil with ≥1 antihypertensive medication
Number of subjects: 15030
Study 35099113 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil with antihypertensive medications
Number of subjects: 15030
Study 34733606 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 54
Study 34733606 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPM)
Number of subjects: 54
Study 32606063 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer influence on tobacco consumption among men; AOR=1.10, 95% CI: 1.05 to 1.16, p<0.01
Number of subjects: 6218
Study 32606063 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement for women; AOR=1.33, 95% CI=1.07 to 1.66, p<0.01
Number of subjects: 6218
Study 34757439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg daily for up to 10 days
Number of subjects: 967
Study 32580164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompting device (watch) to interrupt sedentary behaviors and encourage 10 min of light physical activity (walking) three times a day after meals
Number of subjects: 25
Study 32580164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompting device (watch)
Number of subjects: 25
Study 33228543 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 1573
Study 33228543 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based and facility-based intervention
Number of subjects: 1573
Study 33228543 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1573
Study 36293771 — intervention group
Group type: EXPERIMENTAL
Intervention: High force (HF, ≥2 kg) massage
Number of subjects: 56
Study 36293771 — intervention group
Group type: COMPARATOR
Intervention: Low force (LF, ≤1 kg) massage
Number of subjects: 56
Study 33946565 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific collagen peptides (CP-G) 15 g daily
Number of subjects: 97
Study 33946565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P-G)
Number of subjects: 97
Study 33946565 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP-G)
Number of subjects: 97
Study 36454921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation on Prescription (TCP)
Number of subjects: 250
Study 36454921 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 250
Study 34263662 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cytoreductive surgery (CRS)
Number of subjects: 200
Study 34263662 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 200
Study 35236207 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK inhibitors (JAKis)
Number of subjects: 0
Study 35236207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33992587 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp-based clinical case scenarios educational intervention
Number of subjects: 104
Study 33992587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study 32079742 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent process for a randomized clinical trial (Prettineo)
Number of subjects: 0
Study 32590398 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression-molded polyethylene (CPE) tibial insert
Number of subjects: 300
Study 32590398 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (HXLPE) tibial insert
Number of subjects: 300
Study 32590398 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CPE and HXLPE)
Number of subjects: 300
Study 34525119 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus bevacizumab
Number of subjects: 0
Study 34525119 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 0
Study 33074208 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-related pay (PRP)
Number of subjects: 40
Study 33074208 — intervention group
Group type: COMPARATOR
Intervention: Flat fee payment
Number of subjects: 40
Study 34324472 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch in lactated electrolyte injection (HEX)
Number of subjects: 70
Study 34324472 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NS)
Number of subjects: 70
Study 34324472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh whole blood (FWB)
Number of subjects: 70
Study 33475581 — intervention group
Group type: EXPERIMENTAL
Intervention: Spencer muscle energy technique
Number of subjects: 60
Study 33475581 — intervention group
Group type: COMPARATOR
Intervention: Passive stretching
Number of subjects: 60
Study 35525376 — intervention group
Group type: EXPERIMENTAL
Intervention: CETUX/RT (cetuximab and radiotherapy)
Number of subjects: 304
Study 35525376 — intervention group
Group type: COMPARATOR
Intervention: CIS/RT (cisplatin and radiotherapy)
Number of subjects: 304
Study 33632757 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeout procedure with deliberately introduced errors (wrong name, site, side, allergy, intervention, birthdate, gender)
Number of subjects: 1800
Study 32946536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lot Quality Assurance Sampling (LQAS) following LF-MDA
Number of subjects: 304
Study 35863695 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based mindfulness meditation intervention (MBI), delivered via smartphone app, 10 minutes twice a day for 14 days (total 280 minutes)
Number of subjects: 0
Study 35863695 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation control group, time-matched to the MBI intervention
Number of subjects: 0
Study 33957018 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of recombinant neorudin (EPR‐hirudin, EH) at doses between 0.2 and 2.0 mg/kg by intravenous bolus.
Number of subjects: 62
Study 33957018 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of recombinant neorudin (EPR‐hirudin, EH) at doses of 0.15, 0.30, and 0.45 mg/kg/h.
Number of subjects: 62
Study 33957018 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and continuous administration of recombinant neorudin (EPR‐hirudin, EH).
Number of subjects: 62
Study 34823444 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation RTMS (CTBS-RTMS)
Number of subjects: 40
Study 34823444 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 40
Study 34823444 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (CTBS-RTMS)
Number of subjects: 40
Study 34803913 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1 g/day)
Number of subjects: 12
Study 34803913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35565736 — intervention group
Group type: EXPERIMENTAL
Intervention: myfood24
Number of subjects: 48
Study 35565736 — intervention group
Group type: EXPERIMENTAL
Intervention: myfood24 + diet optimisation
Number of subjects: 48
Study 35565736 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 48
Study 34037070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 181)
Number of subjects: 353
Study 34037070 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 172)
Number of subjects: 353
Study 32597691 — intervention group
Group type: EXPERIMENTAL
Intervention: LC09 herbal compound
Number of subjects: 156
Study 32597691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 35290878 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical progesterone 8% ointment
Number of subjects: 37
Study 35290878 — intervention group
Group type: COMPARATOR
Intervention: Topical clobetasol propionate 0.05% ointment
Number of subjects: 37
Study 34674348 — intervention group
Group type: EXPERIMENTAL
Intervention: RHD patients
Number of subjects: 30
Study 34674348 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 33591390 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high-protein (MHP) diet
Number of subjects: 179
Study 33591390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 179
Study 616173498 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium 1.0 g daily
Number of subjects: 112
Study 616173498 — intervention group
Group type: COMPARATOR
Intervention: Standard CHF therapy
Number of subjects: 112
Study 35099428 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg delta-tocotrienol once daily for 12 weeks
Number of subjects: 77
Study 35099428 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 77
Study 34574832 — intervention group
Group type: EXPERIMENTAL
Intervention: Verily Connect app and Zoom videoconferencing
Number of subjects: 39
Study 34574832 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteering support
Number of subjects: 39
Study 34574832 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 39
Study 35549632 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 450
Study 35549632 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 450
Study 35549632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to change three to four risk behaviors
Number of subjects: 450
Study 33638988 — intervention group
Group type: EXPERIMENTAL
Intervention: Online spaced education (OSE)
Number of subjects: 230
Study 33638988 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure (control)
Number of subjects: 230
Study 32131795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 1 (I1): Ten-minute sequence by the cabaret artist about organ donation.
Number of subjects: 0
Study 32131795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 2 (I2): Ten-minute sequence by the cabaret artist about organ donation plus an organ donor card.
Number of subjects: 0
Study 32131795 — intervention group
Group type: COMPARATOR
Intervention: Control group (C): No specific intervention mentioned.
Number of subjects: 0
Study 36501009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention with food vouchers (120 euros/month for 3 months)
Number of subjects: 66
Study 36501009 — intervention group
Group type: COMPARATOR
Intervention: Control group with food vouchers (120 euros/month for 3 months)
Number of subjects: 66
Study 36501009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 66
Study 36501009 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 33380616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task engagement (Experiment 1)
Number of subjects: 59
Study 33380616 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining to relax (Experiment 2)
Number of subjects: 59
Study 33380616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound pressure level (50 to 70 dB(A))
Number of subjects: 59
Study 33148981 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with co-amoxiclav
Number of subjects: 49
Study 32049971 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic actuator applying forces to shoulders
Number of subjects: 10
Study 32049971 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic actuator applying forces to thigh
Number of subjects: 10
Study 32049971 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic actuator applying forces to shank
Number of subjects: 10
Study 32049971 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic actuator applying forces at higher rates
Number of subjects: 10
Study 33500268 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated nursing team leader
Number of subjects: 120
Study 33500268 — intervention group
Group type: COMPARATOR
Intervention: Traditional roles
Number of subjects: 120
Study 32996146 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air cleaners
Number of subjects: 71
Study 32996146 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 32303180 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mcg norepinephrine bolus
Number of subjects: 110
Study 32303180 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mcg norepinephrine bolus
Number of subjects: 110
Study 32569507 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered motivational interview
Number of subjects: 61
Study 32569507 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 33260468 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment phase of the behavioral weight-loss program
Number of subjects: 182
Study 33260468 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term changes in food addiction (FA)
Number of subjects: 182
Study 33260468 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial reductions in problem food consumption
Number of subjects: 182
Study 34477275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (PO)
Number of subjects: 11
Study 34477275 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen (IV)
Number of subjects: 11
Study 33443907 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic mesh (porcine)
Number of subjects: 165
Study 33443907 — intervention group
Group type: COMPARATOR
Intervention: Synthetic mesh (polypropylene)
Number of subjects: 165
Study 33443907 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic mesh (porcine) under contaminated wound conditions
Number of subjects: 165
Study 33443907 — intervention group
Group type: COMPARATOR
Intervention: Synthetic mesh (polypropylene) under contaminated wound conditions
Number of subjects: 165
Study 33443907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mesh types
Number of subjects: 165